These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 32352753)
41. Design, Synthesis, and Evaluation of Acetylcholinesterase and Butyrylcholinesterase Dual-Target Inhibitors against Alzheimer's Diseases. Guo Y; Yang H; Huang Z; Tian S; Li Q; Du C; Chen T; Liu Y; Sun H; Liu Z Molecules; 2020 Jan; 25(3):. PubMed ID: 31979317 [TBL] [Abstract][Full Text] [Related]
42. Donepezil hydrochloride: a treatment drug for Alzheimer's disease. Sugimoto H Chem Rec; 2001; 1(1):63-73. PubMed ID: 11893059 [TBL] [Abstract][Full Text] [Related]
43. Identification of 1,2,4-Triazolylthioethanone Scaffold for the Design of New Acetylcholinesterase Inhibitors. Fatiha Muhammad E; Kumar A; Wahab HA; Zhang KYJ Mol Inform; 2021 Aug; 40(8):e2100020. PubMed ID: 34060234 [TBL] [Abstract][Full Text] [Related]
44. Myrtenal inhibits acetylcholinesterase, a known Alzheimer target. Kaufmann D; Dogra AK; Wink M J Pharm Pharmacol; 2011 Oct; 63(10):1368-71. PubMed ID: 21899553 [TBL] [Abstract][Full Text] [Related]
45. Design, synthesis and structure-activity relationships of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease. Toda N; Tago K; Marumoto S; Takami K; Ori M; Yamada N; Koyama K; Naruto S; Abe K; Yamazaki R; Hara T; Aoyagi A; Abe Y; Kaneko T; Kogen H Bioorg Med Chem; 2003 May; 11(9):1935-55. PubMed ID: 12670645 [TBL] [Abstract][Full Text] [Related]
46. Latest advances in dual inhibitors of acetylcholinesterase and monoamine oxidase B against Alzheimer's disease. Zou D; Liu R; Lv Y; Guo J; Zhang C; Xie Y J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2270781. PubMed ID: 37955252 [TBL] [Abstract][Full Text] [Related]
47. Xanthone: Potential Acetylcholinesterase Inhibitor for Alzheimer's Disease Treatment. Vanessa VV; Mah SH Mini Rev Med Chem; 2021; 21(17):2507-2529. PubMed ID: 33583373 [TBL] [Abstract][Full Text] [Related]
48. Pharmacophore-based drug design of AChE and BChE dual inhibitors as potential anti-Alzheimer's disease agents. Gao H; Jiang Y; Zhan J; Sun Y Bioorg Chem; 2021 Sep; 114():105149. PubMed ID: 34252860 [TBL] [Abstract][Full Text] [Related]
49. A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease. Toda N; Tago K; Marumoto S; Takami K; Ori M; Yamada N; Koyama K; Naruto S; Abe K; Yamazaki R; Hara T; Aoyagi A; Abe Y; Kaneko T; Kogen H Bioorg Med Chem; 2003 Oct; 11(20):4389-415. PubMed ID: 13129577 [TBL] [Abstract][Full Text] [Related]
50. From dual binding site acetylcholinesterase inhibitors to allosteric modulators: A new avenue for disease-modifying drugs in Alzheimer's disease. Chierrito TPC; Pedersoli-Mantoani S; Roca C; Requena C; Sebastian-Perez V; Castillo WO; Moreira NCS; Pérez C; Sakamoto-Hojo ET; Takahashi CS; Jiménez-Barbero J; Cañada FJ; Campillo NE; Martinez A; Carvalho I Eur J Med Chem; 2017 Oct; 139():773-791. PubMed ID: 28863358 [TBL] [Abstract][Full Text] [Related]
51. Development of an efficient therapeutic agent for Alzheimer's disease: design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter. Toda N; Kaneko T; Kogen H Chem Pharm Bull (Tokyo); 2010 Mar; 58(3):273-87. PubMed ID: 20190429 [TBL] [Abstract][Full Text] [Related]
52. New coumarin-benzotriazole based hybrid molecules as inhibitors of acetylcholinesterase and amyloid aggregation. Singh A; Sharma S; Arora S; Attri S; Kaur P; Kaur Gulati H; Bhagat K; Kumar N; Singh H; Vir Singh J; Mohinder Singh Bedi P Bioorg Med Chem Lett; 2020 Oct; 30(20):127477. PubMed ID: 32781220 [TBL] [Abstract][Full Text] [Related]
53. Tailored Modeling of Rivastigmine Derivatives as Dual Acetylcholinesterase and Butyrylcholinesterase Inhibitors for Alzheimer's Disease Treatment. Adeowo FY; Oyetunji TP; Ejalonibu MA; Ndagi U; Kumalo HM; Lawal MM Chem Biodivers; 2021 Nov; 18(11):e2100361. PubMed ID: 34547176 [TBL] [Abstract][Full Text] [Related]
54. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Davidsson P; Blennow K; Andreasen N; Eriksson B; Minthon L; Hesse C Neurosci Lett; 2001 Mar; 300(3):157-60. PubMed ID: 11226635 [TBL] [Abstract][Full Text] [Related]
55. Discovery of Quinolinone Hybrids as Dual Inhibitors of Acetylcholinesterase and Aβ Aggregation for Alzheimer's Disease Therapy. Manzoor S; Gabr MT; Nafie MS; Raza MK; Khan A; Nayeem SM; Arafa RK; Hoda N ACS Chem Neurosci; 2024 Feb; 15(3):539-559. PubMed ID: 38149821 [TBL] [Abstract][Full Text] [Related]
56. Discovery of novel isoflavone derivatives as AChE/BuChE dual-targeted inhibitors: synthesis, biological evaluation and molecular modelling. Feng B; Li X; Xia J; Wu S J Enzyme Inhib Med Chem; 2017 Dec; 32(1):968-977. PubMed ID: 28718678 [TBL] [Abstract][Full Text] [Related]
57. Synthesis of Benzimidazole-Based Analogs as Anti Alzheimer's Disease Compounds and Their Molecular Docking Studies. Adalat B; Rahim F; Taha M; Alshamrani FJ; Anouar EH; Uddin N; Shah SAA; Ali Z; Zakaria ZA Molecules; 2020 Oct; 25(20):. PubMed ID: 33092223 [TBL] [Abstract][Full Text] [Related]
59. Discovery of novel 2,3-dihydro-1H-inden-1-ones as dual PDE4/AChE inhibitors with more potency against neuroinflammation for the treatment of Alzheimer's disease. Liu J; Liu L; Zheng L; Feng KW; Wang HT; Xu JP; Zhou ZZ Eur J Med Chem; 2022 Aug; 238():114503. PubMed ID: 35689855 [TBL] [Abstract][Full Text] [Related]